The Valens Company (TSX: VLNS) appears to be pulling ahead as the premier cannabis extractor as of late, this morning announcing a new custom manufacturing agreement with boutique brand house FPS Brands Inc. The company will effectively be helping to launch a new line of hemo-derived CBD products under the brand name ufeelu.
The agreement announced this morning is for a two year term, wherein the company will produce a minimum of 250,000 units across a variety of product segments. Stated products are to include topicals, oils and vapes, with specialty drinks to be added to the lineup in the near term.
Valens appears to be taking care of any process related to the regulated substance, including providing extracts, filling, packaging, manufacturing and distribution. For this, a fee will be generated on each product that is equal to the predetermined wholesale price of each unit, in addition to a brokerage fee on monthly revenue.
It appears that FPS Brands will largely be providing the marketing function of the product, while collecting revenue upon the sale of products to provincial retailers. A minimum deposit will be provided upfront by the firm.
A dollar value was not ascribed to the transaction, as has become standard within the extraction segment as of late. Products are expected to hit store shelves this fall.
The Valens Company last traded at $2.66 on the TSX.
Information for this briefing was found via Sedar and The Valens Company. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.